What question did this study set out to answer?

The aim is to assess the impact of neoadjuvant therapy on the management and outcomes of resectable advanced melanoma.

June 20, 2026CancersOpen Access

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma

View Full Paper

Ask AI

Bookmark

The aim is to assess the impact of neoadjuvant therapy on the management and outcomes of resectable advanced melanoma.
Included prospective trials such as OpACIN, OpACIN-neo, and NADINA, focusing on neoadjuvant therapies like ipilimumab and nivolumab.
Evaluated treatment response and its correlation with surgical intervention and long-term survival outcomes.
Showed high pathological response rates with neoadjuvant therapy, indicating potential for enhanced surgery results.
Demonstrated improved event-free survival with perioperative pembrolizumab compared to adjuvant therapy alone.

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates neoadjuvant treatment strategies in resectable advanced melanoma, suggesting improved outcomes.

Papadopoulos et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark